Jacobs Levy Equity Management’s Amedisys AMED Stock Holding History

Jacobs Levy Equity Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,932	Closed	-$333K	–	994
2022 Q1	$333K	Buy	+1,932	New	+$289K	﹤0.01%	906
2019 Q4	–	Sell	-18,060	Closed	-$2.37M	–	991
2019 Q3	$2.37M	Buy	18,060 +2,400	+15%	+$312K	0.03%	476
2019 Q2	$1.9M	Buy	+15,660	New	+$1.86M	0.03%	534
2014 Q4	–	Sell	-30,070	Closed	-$607K	–	812
2014 Q3	$607K	Buy	+30,070	New	+$580K	0.01%	578
2013 Q4	–	Sell	-36,945	Closed	-$636K	–	935
2013 Q3	$636K	Buy	+36,945	New	+$548K	0.01%	629

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Jacobs Levy Equity Management's AMED Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Amedisys (AMED) in Q2 2022, closing a stake of 1,932 shares — an estimated $333K sold.

Jacobs Levy Equity Management first reported a position in AMED in Q3 2013 and held it in 5 quarters. The position peaked at $2.37M in Q3 2019. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 1,932 Amedisys shares in Q2 2022, an estimated $333K.
Jacobs Levy Equity Management first reported a position in Amedisys in Q3 2013 and held it in 5 quarters.
Jacobs Levy Equity Management's Amedisys position peaked at $2.37M in Q3 2019.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.